Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Thrombotic thrombocytopenic purpura

Thrombotic thrombocytopenic purpura

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Thrombotic thrombocytopenic purpura

3 trials tracked for Thrombotic thrombocytopenic purpura: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 73 citations.

3Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2 Phase 2 1
  1. Phase 3 Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) Completed · 73 cited
  2. Phase 3 Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura Completed · 2 cited
  3. Phase 2 Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Completed

Showing the 3 most-cited and recently-updated of 3 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials
Hematology Meta-analysis
Recombinant ADAMTS13 shows no significant difference in acute TTP events versus standard therapy or placebo in phase 2 and 3 trials New drug raises enzyme levels but shows no clear benefit over standard care for TTP
This systematic review and meta-analysis evaluates recombinant ADAMTS13 in patients with congenital or acquired thrombotic thrombocytopenic …
A new treatment boosts enzyme activity in blood disorders but offers no clear advantage over standard therapy based on current evidence.
Jun 1, 2026
Meta-analysis links HLA alleles and ADAMTS13 variants to thrombotic thrombocytopenic purpura risk
Hematology Meta-analysis
Meta-analysis links HLA alleles and ADAMTS13 variants to thrombotic thrombocytopenic purpura risk Your Genes Could Predict Your Risk of This Rare Blood Disorder
This systematic review and meta-analysis synthesizes genetic associations in immune and congenital thrombotic thrombocytopenic purpura. HLA-…
Your DNA may hold clues to whether you will develop a rare but dangerous blood clotting condition, and new research is finally mapping those…
May 9, 2026